Literature DB >> 14646192

Adenovirus-mediated suicide gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter induced apoptosis of ovarian cancer cell line.

Joon-Seok Song1, Hyun-Pyo Kim, Won-Suck Yoon, Kyu-Wan Lee, Mee-Hye Kim, Kyung-Tai Kim, Hy-Sook Kim, Young Tae Kim.   

Abstract

Telomerase is a ribonucleoprotein complex the function of which is to add telomeric repeats (TTAGGG)(n) to chromosomal ends, and it is known to play an important role in cellular immortalization. Telomerase is highly active in most tumor cells, yet not in normal cells. As such, it may have possible applications in cancer gene therapy. Telomerase consists of two essential components, telomerase RNA template (hTR) and catalytic subunit (hTERT). hTERT is expressed only in cells and tissues positive for telomerase activity, i.e., tumor and fetal cells. We here tested the possibility of the utilization of the hTERT promoter in targeted cancer gene therapy. We cloned the hTERT promoter in the replace of the CMV promoter and sub-cloned HSV-TK gene to be controlled by hTERT gene promoter in adenovirus shuttle plasmid. Then we constructed recombinant adenovirus Ad-hT-TK, and infected them into normal and human gynecological cancer cell lines. Through these experiments, we identified the selective tumor specific cell death by Ad-hT-TK. Furthermore, FACS analysis and TUNEL assay suggests that the reduced viability is mediated through the induction of apoptosis, indicating that this approach may be a useful method for suppressing cancer growth in targeted cancer gene therapy. These results show that Ad-hT-TK could be used for gynecological cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14646192     DOI: 10.1271/bbb.67.2344

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  9 in total

1.  Identification and functional characterization of glioma-specific promoters and their application in suicide gene therapy.

Authors:  Toshio Yawata; Yusuke Maeda; Makiko Okiku; Eri Ishida; Kazuhiro Ikenaka; Keiji Shimizu
Journal:  J Neurooncol       Date:  2011-02-24       Impact factor: 4.130

Review 2.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

3.  Suicide Gene Therapy for Cancer - Current Strategies.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Antonios Sakkas; Lonny Yarmus; Haidong Huang; Qiang Li; Lutz Freitag; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-08-09

4.  A programmable NOR-based device for transcription profile analysis.

Authors:  Tom Ran; Yehonatan Douek; Lilach Milo; Ehud Shapiro
Journal:  Sci Rep       Date:  2012-09-07       Impact factor: 4.379

5.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

6.  Targeted antitumor effect induced by hTERT promoter mediated ODC antisense adenovirus.

Authors:  Wei Wang; Bin Jin; Wei Li; Chun-Xiao Xu; Fu-Ai Cui; Bin Liu; Yun-Fei Yan; Xian-Xi Liu; Xiu-Li Wang
Journal:  Mol Biol Rep       Date:  2009-10-30       Impact factor: 2.316

7.  The retrovirus-mediated antisense human telomerase RNA (hTR) gene limits the growth of hepatocellular carcinoma growth in cell culture and animals.

Authors:  Ji-yong Liu; Qiang Zhu; Jianfeng Li; Shulei Zhao; Luning Li
Journal:  Dig Dis Sci       Date:  2007-10-12       Impact factor: 3.199

8.  Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer.

Authors:  Cong-Xiang Shen; Zhong Wen; Yu-Hong Qian; Shao-Feng Mu; Xiao-Fang Guan
Journal:  J Exp Clin Cancer Res       Date:  2010-07-13

9.  Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines.

Authors:  Antonios Sakkas; Paul Zarogoulidis; Kalliopi Domvri; Wolfgang Hohenforst-Schmidt; Dimitris Bougiouklis; Stylianos Kakolyris; Thomas Zarampoukas; Ioannis Kioumis; Georgia Pitsiou; Haidong Huang; Qiang Li; Soultana Meditskou; Theodora Tsiouda; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  J Cancer       Date:  2014-04-17       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.